ImmunoGen, Inc.

ImmunoGen, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. ImmunoGen, Inc. is not a good value stock. ImmunoGen, Inc. is not very popular among insiders. ImmunoGen, Inc. is a mediocre stock to choose.

ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-dru...

News

AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals

SeekingAlpha.com: All News no summary\n more…

Citigroup Inc. Acquires 50,869 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)

Zolmax Citigroup Inc. increased its holdings in ImmunoGen, Inc. (NASDAQ:IMGN Free Report) by 26.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange...\n more…

Charles Schwab Investment Management Inc. Acquires 20,113 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)

Zolmax Charles Schwab Investment Management Inc. increased its holdings in shares of ImmunoGen, Inc. (NASDAQ:IMGN Free Report) by 1.1% in the 3rd quarter, according to its most recent disclosure...\n more…

ImmunoGen, Inc. (NASDAQ:IMGN) Shares Acquired by Rafferty Asset Management LLC

Ticker Report Rafferty Asset Management LLC grew its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN Free Report) by 68.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 566,985...\n more…

StockNews.com Begins Coverage on ImmunoGen (NASDAQ:IMGN)

Ticker Report StockNews.com started coverage on shares of ImmunoGen (NASDAQ:IMGN Free Report) in a research note released on Wednesday morning. The brokerage issued a hold rating on the biotechnology...\n more…

ImmunoGen (NASDAQ:IMGN) Now Covered by Analysts at StockNews.com

Zolmax StockNews.com assumed coverage on shares of ImmunoGen (NASDAQ:IMGN Free Report) in a research note published on Wednesday morning. The firm issued a hold rating on the biotechnology...\n more…